Literature DB >> 9010701

Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.

L Poulsen1, K Brøsen, L Arendt-Nielsen, L F Gram, K Elbaek, S H Sindrup.   

Abstract

OBJECTIVE: Codeine O-demethylation to morphine is catalysed by the genetic polymorphic sparteine oxygenase (CYP2D6). The objective of the present study was to assess the analgesic effect of codeine on different types of experimental pain in relation to sparteine phenotype.
METHODS: Fourteen extensive (EMs) and 14 poor metabolizers (PMs) of sparteine completed a randomized, double-blind, three-way, cross-over study with a single oral dose of codeine (75 or 100 mg) against morphine (20 or 30 mg) and placebo. Pain tests performed before and 1, 2, 3, and 4 h after medication included the cold pressor test and pain thresholds for heat and pressure stimulation. Adverse effects were rated by a structured interview.
RESULTS: After morphine, morphine and morphine-6-glucuronide were present in equal amounts in plasma of PMs and EMs. After codeine, neither morphine nor morphine-6-glucuronide could be detected in 13 of the 14 PMs, whereas at least one of the compounds could be detected in all EMs. Peak pain and discomfort rated on a VAS scale during the cold pressor test were significantly reduced by morphine in both EMs and PMs, with a median peak change of 8.5 and 7.0 mm, respectively, for peak pain, and 11.5 and 15.5 mm, respectively, for discomfort. Codeine only reduced these pain measures significantly in EMs, with a median peak change of 5.5 mm for peak pain and 10.5 mm for discomfort. Pain detection and tolerance thresholds to heat and pressure were not consistently altered by either morphine or codeine. In PMs, adverse effects were significantly more pronounced on morphine than on codeine and only showed a slight difference between codeine and placebo. In EMs, there was no difference between codeine and morphine and more pronounced adverse effects on both drugs as compared to placebo.
CONCLUSION: This study confirms that codeine O-demethylation depends on CYP2D6; it shows that the 6-glucuronidation of morphine is independent of CYP2D6; it supports the theory that the analgesic effect of codeine depends on its O-demethylation; and it indicates that this is probably also the case for the adverse effects. The results lend no support to the suggestion of a non-opioid analgesic effect of codeine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9010701     DOI: 10.1007/s002280050200

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  45 in total

Review 1.  [Genetics, pain and analgesia].

Authors:  U Stamer; B Bayerer; F Stüber
Journal:  Anaesthesist       Date:  2006-07       Impact factor: 1.041

Review 2.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 4.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  A limited number of prescribed drugs account for the great majority of drug-drug interactions.

Authors:  Johan Holm; Birgit Eiermann; Erik Eliasson; Buster Mannheimer
Journal:  Eur J Clin Pharmacol       Date:  2014-09-06       Impact factor: 2.953

Review 6.  The genetic mediation of individual differences in sensitivity to pain and its inhibition.

Authors:  J S Mogil
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 7.  Genetic variability of pain perception and treatment--clinical pharmacological implications.

Authors:  Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2011-02-23       Impact factor: 2.953

8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 9.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 10.  Genes associated with addiction: alcoholism, opiate, and cocaine addiction.

Authors:  Mary Jeanne Kreek; David A Nielsen; K Steven LaForge
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.